Insider Trading Alert - RPTP, TEAR And ISRG Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Nov. 25, 2014, 127 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $158.00 to $38,255,692.50.

Highlighted Stocks Traded by Insiders:

Raptor Pharmaceutical (RPTP) - FREE Research Report

Sager Erich, who is Director at Raptor Pharmaceutical, sold 46,966 shares at $10.35 on Nov. 25, 2014. Following this transaction, the Director owned 27,331 shares meaning that the stake was reduced by 63.21% with the 46,966-share transaction.

The shares most recently traded at $9.39, down $0.96, or 10.27% since the insider transaction. Historical insider transactions for Raptor Pharmaceutical go as follows:

  • 4-Week # shares bought: 16,100
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 16,100
  • 12-Week # shares sold: 10,000
  • 24-Week # shares bought: 16,100
  • 24-Week # shares sold: 10,000

The average volume for Raptor Pharmaceutical has been 610,000 shares per day over the past 30 days. Raptor Pharmaceutical has a market cap of $630.6 million and is part of the health care sector and drugs industry. Shares are down 24.65% year-to-date as of the close of trading on Tuesday.

Raptor Pharmaceuticals Corp., a biopharmaceutical company, focuses on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases. Currently, there are 2 analysts who rate Raptor Pharmaceutical a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on RPTP - FREE

TheStreet Quant Ratings rates Raptor Pharmaceutical as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and generally high debt management risk. Get the full Raptor Pharmaceutical Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TearLab (TEAR) - FREE Research Report

Karpecki Paul, who is Director at TearLab, bought 18,500 shares at $2.40 on Nov. 25, 2014. Following this transaction, the Director owned 22,000 shares meaning that the stake was boosted by 528.57% with the 18,500-share transaction.

The shares most recently traded at $2.90, up $0.50, or 17.3% since the insider transaction. Historical insider transactions for TearLab go as follows:

  • 4-Week # shares bought: 43,375
  • 12-Week # shares bought: 43,375
  • 12-Week # shares sold: 7,000
  • 24-Week # shares bought: 136,375
  • 24-Week # shares sold: 7,000

The average volume for TearLab has been 242,800 shares per day over the past 30 days. TearLab has a market cap of $101.1 million and is part of the health care sector and health services industry. Shares are down 68.95% year-to-date as of the close of trading on Tuesday.

TearLab Corp. operates as an ophthalmic device company in the United States. It is involved in developing and commercializing TearLab Osmolarity System, a proprietary in vitro diagnostic tear testing platform that measures tear film osmolarity for the diagnosis of dry eye disease. Currently, there are 3 analysts who rate TearLab a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TEAR - FREE

TheStreet Quant Ratings rates TearLab as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full TearLab Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Intuitive Surgical (ISRG) - FREE Research Report

Samath Jamie, who is VP & Principal Accounting Offi at Intuitive Surgical, sold 61 shares at $520.00 on Nov. 25, 2014. Following this transaction, the VP & Principal Accounting Offi owned 0 shares meaning that the stake was reduced by 100% with the 61-share transaction.

The shares most recently traded at $513.70, down $6.30, or 1.23% since the insider transaction. Historical insider transactions for Intuitive Surgical go as follows:

  • 4-Week # shares sold: 82
  • 12-Week # shares sold: 82
  • 24-Week # shares sold: 82

The average volume for Intuitive Surgical has been 323,700 shares per day over the past 30 days. Intuitive Surgical has a market cap of $18.9 billion and is part of the health care sector and health services industry. Shares are up 34.47% year-to-date as of the close of trading on Tuesday.

Intuitive Surgical, Inc. designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories. The company has a P/E ratio of 45.5. Currently, there are 10 analysts who rate Intuitive Surgical a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ISRG - FREE

TheStreet Quant Ratings rates Intuitive Surgical as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Intuitive Surgical Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists